Cynapsus Therapeutics Inc. (NASDAQ:CYNA) shares reached a new 52-week high on Thursday . The stock traded as high as $39.74 and last traded at $39.66, with a volume of 5,626,511 shares. The stock had previously closed at $18.36.

Several research analysts have weighed in on the company. Janney Montgomery Scott lowered Cynapsus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday. Noble Financial reissued a “buy” rating and set a $50.00 target price on shares of Cynapsus Therapeutics in a report on Tuesday. Finally, BMO Capital Markets set a $30.00 target price on Cynapsus Therapeutics and gave the stock a “buy” rating in a report on Tuesday, August 16th.

The company’s 50 day moving average is $18.69 and its 200 day moving average is $14.83. The firm’s market cap is $492.47 million.

Cynapsus Therapeutics (NASDAQ:CYNA) last posted its quarterly earnings data on Thursday, August 11th. The company reported $0.83 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.77) by $1.60. Equities research analysts forecast that Cynapsus Therapeutics Inc. will post ($3.15) earnings per share for the current year.

Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.